Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY, USA.
Nat Commun. 2022 Feb 16;13(1):903. doi: 10.1038/s41467-022-28450-1.
V2p and V2i antibodies (Abs) that are specific for epitopes in the V1V2 region of the HIV gp120 envelope (Env) do not effectively neutralize HIV but mediate Fc-dependent anti-viral activities that have been correlated with protection from, or control of HIV, SIV and SHIV infections. Here, we describe a novel molecular toolbox that allows the discrimination of antigenically and functionally distinct polyclonal V2 Ab responses. We identify different patterns of V2 Ab induction by SHIV infection and three separate vaccine regimens that aid in fine-tuning an optimized immunization protocol for inducing V2p and V2i Abs. We observe no, or weak and sporadic V2p and V2i Abs in non-vaccinated SHIV-infected NHPs, but strong V2p and/or V2i Ab responses after immunization with a V2-targeting vaccine protocol. The V2-focused vaccination is superior to both natural infection and to immunization with whole Env constructs for inducing functional V2p- and V2i-specific responses. Strikingly, levels of V2-directed Abs correlate inversely with Abs specific for peptides of V3 and C5. These data demonstrate that a V1V2-targeting vaccine has advantages over the imprecise targeting of SIV/SHIV infections and of whole Env-based immunization regimens for inducing a more focused functional V2p- and V2i-specific Ab response.
V2p 和 V2i 抗体(Abs)是针对 HIV gp120 包膜(Env)的 V1V2 区域中的表位特异性的,但不能有效中和 HIV,但介导 Fc 依赖性抗病毒活性,这些活性与免受 HIV、SIV 和 SHIV 感染的保护或控制相关。在这里,我们描述了一个新的分子工具箱,该工具可以区分具有不同抗原性和功能的多克隆 V2 Ab 反应。我们确定了 SHIV 感染和三种不同疫苗方案引起的不同的 V2 Ab 诱导模式,这些模式有助于微调诱导 V2p 和 V2i Abs 的最佳免疫方案。我们观察到未接种 SHIV 感染的非人类灵长类动物(NHPs)中没有或只有微弱和零星的 V2p 和 V2i Abs,但在 V2 靶向疫苗方案免疫后会产生强烈的 V2p 和/或 V2i Ab 反应。V2 为重点的疫苗接种优于自然感染和整个 Env 结构免疫接种,可诱导功能性 V2p-和 V2i-特异性反应。引人注目的是,V2 定向 Abs 的水平与针对 V3 和 C5 肽的 Abs 呈负相关。这些数据表明,V1V2 靶向疫苗比 SIV/SHIV 感染的不精确靶向和整个 Env 为基础的免疫方案具有优势,可诱导更集中的功能性 V2p-和 V2i-特异性 Ab 反应。